Atherotech Diagnostics Lab Release: Improved Heart Disease Risk Assessment Achieved in At-Risk and Hidden-Risk Populations With VAP® Lipid Panel
11/7/2012 10:43:18 AM
LOS ANGELES--(BUSINESS WIRE)--Researchers using the Atherotech VAP® Lipid Panel demonstrated the comprehensive lipid profile’s accuracy in risk stratification through subclass measurement in two abstracts presented today at the American Heart Association (AHA) Scientific Sessions 2012. The VAP Lipid Panel measured cholesterol subclasses in Framingham and TRIUMPH populations, highlighting the lipid panel’s accuracy and potential for improved outcomes in personalized heart disease risk assessment compared to the standard lipid panel, which is inadequate and inaccurate in select patients.
comments powered by